QIAGEN Current Ratio 2010-2022 | QGEN

Current and historical current ratio for QIAGEN (QGEN) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. QIAGEN current ratio for the three months ending September 30, 2022 was 1.84.
QIAGEN Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $2.76B $1.50B 1.84
2022-06-30 $2.15B $0.96B 2.23
2022-03-31 $2.10B $0.96B 2.19
2021-12-31 $2.11B $1.52B 1.39
2021-09-30 $2.03B $1.07B 1.90
2021-06-30 $1.80B $0.50B 3.58
2021-03-31 $1.67B $0.50B 3.34
2020-12-31 $1.62B $0.57B 2.84
2020-09-30 $1.59B $1.09B 1.46
2020-06-30 $1.64B $0.96B 1.71
2020-03-31 $1.58B $1.00B 1.58
2019-12-31 $1.57B $0.95B 1.65
2019-09-30 $1.54B $0.63B 2.45
2019-06-30 $1.61B $0.91B 1.77
2019-03-31 $1.60B $0.94B 1.69
2018-12-31 $2.16B $0.97B 2.22
2018-09-30 $1.87B $1.37B 1.37
2018-06-30 $1.69B $0.94B 1.79
2018-03-31 $1.75B $0.82B 2.14
2017-12-31 $1.65B $0.33B 5.07
2017-09-30 $1.57B $0.30B 5.33
2017-06-30 $1.16B $0.30B 3.85
2017-03-31 $0.76B $0.27B 2.79
2016-12-31 $1.04B $0.31B 3.36
2016-09-30 $0.96B $0.25B 3.85
2016-06-30 $0.90B $0.25B 3.63
2016-03-31 $0.96B $0.25B 3.91
2015-12-31 $0.96B $0.27B 3.58
2015-09-30 $0.98B $0.28B 3.52
2015-06-30 $0.93B $0.27B 3.51
2015-03-31 $0.96B $0.33B 2.88
2014-12-31 $1.15B $0.43B 2.66
2014-09-30 $1.27B $0.44B 2.91
2014-06-30 $1.20B $0.30B 4.06
2014-03-31 $1.22B $0.31B 3.88
2013-12-31 $0.92B $0.34B 2.73
2013-09-30 $0.87B $0.30B 2.88
2013-06-30 $0.90B $0.30B 3.04
2013-03-31 $0.98B $0.27B 3.66
2012-12-31 $0.99B $0.27B 3.72
2012-09-30 $0.80B $0.54B 1.49
2012-06-30 $0.74B $0.51B 1.45
2012-03-31 $0.76B $0.45B 1.68
2011-12-31 $0.75B $0.45B 1.65
2011-09-30 $0.97B $0.65B 1.50
2011-06-30 $1.41B $0.37B 3.85
2011-03-31 $1.39B $0.38B 3.70
2010-12-31 $1.37B $0.39B 3.51
2010-09-30 $1.35B $0.40B 3.42
2010-06-30 $1.35B $0.32B 4.20
2010-03-31 $1.33B $0.34B 3.94
2009-12-31 $1.33B $0.38B 3.55
2009-09-30 $1.37B $0.38B 3.65
2009-06-30 $0.79B $0.26B 2.97
2009-03-31 $0.71B $0.22B 3.17
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.120B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00